MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8875-8889

  Han, Kang ^a,c   Chen, Xiang ^b   Bian, Na ^c   Ma, Baoan ^c   Yang, Tongtao ^c   Cai, Chengkui ^c   Fan, QingYu ^c   Zhou, Yong ^c   Zhao, TingBao ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CCND1; Metastatic; MicroRNA; miR 195; Osteosarcoma

Indexed keywords

CYCLIN D1; MICRORNA; MICRORNA 195; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; HYBRID PROTEIN; MIRN195 MICRORNA, HUMAN; RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CCND1 GENE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; OVERALL SURVIVAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; ADOLESCENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; NUDE MOUSE; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; TISSUE MICROARRAY; TRANSPLANTATION; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROPORTIONAL HAZARDS MODELS; RECOMBINANT FUSION PROTEINS; RNA, NEOPLASM; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84928719414     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3560     Document Type: Article

References (33)

1. Mirabello L, Troisi RJ and Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-1543.
2. Chou AJ, Geller DS and Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatric drugs. 2008; 10(5):315-327.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
4. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nature reviews Molecular cell biology. 2005; 6(5):376-385.
5. Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS. Posttranscriptional gene silencing by siRNAs and miRNAs. Current opinion in structural biology. 2005; 15(3):331-341.
6. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107(7):823-826.
7. He L and Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews Genetics. 2004; 5(7):522-531.
8. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A and Tuschl T. New microRNAs from mouse and human. RNA (New York, NY). 2003; 9(2):175-179.
9. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129(7):1401-1414.
10. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva-Jr WA, Falcao RP and Zago MA. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al]. 2007; 40(11):1435-1440.
11. Bhattacharya A, Schmitz U, Wolkenhauer O, Schonherr M, Raatz Y and Kunz M. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene. 2013; 32(26):3175-3183.
12. Wang X, Wang J, Ma H, Zhang J and Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Medical oncology (Northwood, London, England). 2012; 29(2):919-927.
13. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (Baltimore, Md). 2009; 50(1):113-121.
14. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG and Sidhu SB. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(24):7684-7692.
15. Li Z, Wang C, Prendergast GC and Pestell RG. Cyclin D1 functions in cell migration. Cell cycle (Georgetown, Tex). 2006; 5(21):2440-2442.
16. Arnold A and Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(18):4215-4224.
17. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004; 145(12):5439-5447.
18. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ and Baak JP. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. The American journal of pathology. 1997; 150(2):705-711.
19. Chen X, Yang TT, Wang W, Sun HH, Ma BA, Li CX, Ma Q, Yu Z and Fan QY. Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology. 2009; 61(1-2):37-44.
20. Chen X, Yang TT, Zhou Y, Wang W, Qiu XC, Gao J, Li CX, Long H, Ma BA, Ma Q, Zhang XZ, Yang LJ and Fan QY. Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma. Molecular carcinogenesis. 2014; 53(2):138-144.
21. Chen X, Yang TT, Qiu XC, Ji ZG, Li CX, Long H, Zhou Y, Ma BA, Ma Q, Zhang X and Fan QY. Gene expression profiles of human osteosarcoma cell sublines with different pulmonary metastatic potentials. Cancer biology & therapy. 2011; 11(2):287-292.
22. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology (Baltimore, Md). 2013; 58(2):642-653.
23. Arndt CA, Rose PS, Folpe AL and Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clinic proceedings Mayo Clinic. 2012; 87(5):475-487.
24. Luetke A, Meyers PA, Lewis I and Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer treatment reviews. 2014; 40(4):523-532.
25. Morozova N, Zinovyev A, Nonne N, Pritchard LL, Gorban AN and Harel-Bellan A. Kinetic signatures of microRNA modes of action. RNA (New York, NY). 2012; 18(9):1635-1655.
26. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T and Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. The American journal of pathology. 1997; 151(1):161-168.
27. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, Li Z, Yao TP and Pestell RG. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. The Journal of biological chemistry. 2005; 280(17):16934-16941.
28. Grenman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. International journal of cancer Journal international du cancer. 1989; 44(1):131-136.
29. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer research. 1986; 46(8):4109-4115.
30. Pan Z, Zhao W, Zhang X, Wang B, Wang J, Sun X, Liu X, Feng S, Yang B and Lu Y. Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFbeta1 expression and activation of p38-MAPK and ERK1/2. British journal of pharmacology. 2011; 162(3):688-700.
31. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q and Ma B. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS one. 2013; 8(1):e53906.
32. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M and Ochiya T. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Molecular therapy :the journal of the American Society of Gene Therapy. 2011; 19(6):1123-1130.
33. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D and Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of biological chemistry. 2010; 285(23):17869-17879.